Atopic dermatitis
Conditions
Interventions
experimental group:Desonide Cream/Eloson Cream
control group:Desonide Cream/Eloson Cream
Sponsors
Beijing Children's Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 12 Years
Inclusion criteria
Inclusion criteria: 1. Children from 0 to 12 years old (<= 12 years old) are male or female; 2. Children with atopic dermatitis meeting AADC (American Academy of Dermatology consensus) criteria; 3. Subjects with moderate atopic dermatitis: IgA score: 3; And 7.1 <= EASI <= 21; 4. The subjects and their guardians are willing to use the study drug in strict accordance with the guidance of the researchers during the whole study period, and do not use other similar products; 5. The guardian of the subjects can fully understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent, and cooperate with the clinical follow-up and diary card filling.
Exclusion criteria
Exclusion criteria: 1. Children with skin diseases other than atopic dermatitis in the area requiring treatment; 2. Children in acute stage with erosion, exudation and secondary infection; 3. Children who have participated in clinical trials of other drugs or medical devices in recent 3 months; 4. Children who are known to be allergic to any component or test substance in Desonide ointment / eloxone cream; 5. Subjects who used emollients for less than 1 week before enrollment; The withdrawal time of antihistamines was less than 1 week; Local use of corticosteroids or other immunosuppressants for less than 2 weeks; The withdrawal time of systemic corticosteroids and other immunosuppressants (cyclosporine, methotrexate, Tripterygium wilfordii, etc.) was less than 4 weeks; Children whose phototherapy stopped for less than 6 weeks; 6. Children with severe systemic diseases (such as cardiovascular system, respiratory system, digestive system, nervous system, endocrine system, urogenital system diseases, etc.) and immunodeficiency diseases; 7. Subjects with poor compliance, or known to be unable to participate in the follow-up on time, or unwilling to comply with the study protocol during the study period; 8. Children who are not suitable to participate in this clinical trial according to the judgment of the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maintenance rate;Recurrence time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dosage of hormone;Lesion area;Pruritus severity assessment;Sleep disorder assessment;Skin pH;IDQOL;CDQOL;DFI; | — |
Countries
China
Contacts
Public ContactLin Ma
Beijing Children's Hospital Affiliated to Capital Medical University
Outcome results
None listed